An interventional study of rTMS Treatment in Obsessive-Compulsive Disorder, sponsored by Centre Hospitalier Henri Laborit. Recruiting at 2 sites in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Centre Hospitalier Henri Laborit · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Obsessive-Compulsive Disorder with a site in France — 5 open to participants now, 6 under way, none of them phase 3. Obsessive-Compulsive Disorder · France.
Among the 20 studies in Obsessive-Compulsive Disorder with a site in France, this one is the 2nd largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2021, is one of 14 with no phase, and was the 17th registered.
637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.
Browse Obsessive-Compulsive Disorder studies →5 of the 20 studies in Obsessive-Compulsive Disorder with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier St Anne · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+
Centre Hospitalier Henri Laborit · Sites in France
Ages 18–70
University Hospital, Grenoble · Sites in France, Germany, Sweden and 1 more country
Ages 18–69
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 2
First in 2005; this study’s year is marked. 1 started in 2021.
This study's planned enrollment of 136 is above the median of 45 across 522 interventional studies indexed under Obsessive-Compulsive Disorder.
Median enrollment 45 across the 18 interventional studies, 7 across the 2 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 20 has an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Henri Laborit is the lead sponsor of 27 studies on the registry; 17 are open to participants now.
Centre Hospitalier Henri Laborit has 4 studies filed under Obsessive-Compulsive Disorder — fewer than ten, so there is no comparison to draw.
2 of the studies in Obsessive-Compulsive Disorder with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06017713Centre Hospitalier Henri LaborittDCS Associated With Symptom Provocation in the Management of Patients With Resistant Obsessive Compulsive Disorder | 2027-04 |
| NCT04934007Centre Hospitalier Henri LaboritBilateral Lateral OFC rTMS in Obsessive Compulsive Disorder | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Obsessive-Compulsive Disorder with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
According to the literature the lateral part of the Orbito Frontal Cortex (lOFC) is a relevant bilateral target for repetitive Trans-cranial Magnetic Stimulation (rTMS) in Obsessive Compulsive Disorder (OCD). Both hemispheres are concerned in terms of target.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active rTMS stimulation , 2 session per day during 10 days.
Device: rTMS Treatment
Sham rTMS stimulation , 2 session per day during 10 days.
Device: rTMS Treatment
1 Hz rTMS
Yale Brown Obsessive Compulsive Scale score
Significant clinical change (≥ 25%) from baseline to two weeks after the treatment sequence, assessed by a significant reduction in YBOCS scores at day 25
Time frame: baseline and 25 days
Yale Brown Obsessive Compulsive Scale
Significant clinical change of the YBOCS score (≥25% decrease), from baseline to day 70
Time frame: baseline and 70 days
general assessement functioning (GAF)
Change of the general assessement functioning (GAF) at day 25
Time frame: baseline and 25 days
general assessement functioning (GAF)
Change of the general assessement functioning (GAF) at day 70
Time frame: baseline and 70 days
Clinical Global Impression (CGI)
Clinical Global Impressions (CGI) change at day 25
Time frame: baseline and 25 days
Clinical Global Impression (CGI)
Clinical Global Impressions (CGI) change at day 70
Time frame: baseline and 70 days
Adverse events linked to the rTMS treatment
Number and types of adverse events linked to the rTMS treatment
Time frame: 70 days
Started Sep 2021 (actual). Primary completion is estimated for Sep 2027, 72 months after the start.
Of 235 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's planned 72 months is above that.
Counting every sponsor, half of 238 studies reached it within 43 months; a quarter within 22 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Obsessive-Compulsive Disorder →
Centre Hospitalier Henri Laborit